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Runx1 deﬁciency permits granulocyte lineage commitment
but impairs subsequent maturation
KP Ng1,5, Z Hu1,2,5, Q Ebrahem1, S Negrotto1, J Lausen3 and Y Saunthararajah1,4
First-hits in the multi-hit process of leukemogenesis originate in germline or hematopoietic stem cells (HSCs), yet leukemia-
initiating cells (LICs) usually have a lineage-committed phenotype. The molecular mechanisms underlying this compartment shift
during leukemia evolution have not been a major focus of investigation and remain poorly understood. Here a mechanism
underlying this shift was examined in the context of Runx1 deﬁciency, a frequent leukemia-initiating event. Lineage-negative cells
isolated from the bone marrow of Runx1-haploinsufﬁcient and wild-type control mice were cultured in granulocyte-colony-
stimulating factor to force lineage commitment. Runx1-haploinsufﬁcient cells demonstrated signiﬁcantly greater and persistent
exponential cell growth than wild-type controls. Not surprisingly, the Runx1-haploinsufﬁcient cells were differentiation-impaired, by
morphology and by ﬂow-cytometric evaluation for granulocyte differentiation markers. Interestingly, however, this impaired
differentiation was not because of decreased granulocyte lineage commitment, as RNA and protein upregulation of the master
granulocyte lineage-commitment transcription factor Cebpa, and Hoxb4 repression, was similar in wild-type and Runx1-
haploinsufﬁcient cells. Instead, RNA and protein expression of Cebpe, a key driver of progressive maturation after lineage
commitment, were signiﬁcantly decreased in Runx1-haploinsufﬁcient cells. Primary acute myeloid leukemia cells with normal
cytogenetics and RUNX1 mutation also demonstrated this phenotype of very high CEBPA mRNA expression but paradoxically low
expression of CEBPE, a CEBPA target gene. Chromatin-immunoprecipitation analyses suggested a molecular mechanism for this
phenotype: in wild-type cells, Runx1 binding was substantially greater at the Cebpe than at the Cebpa enhancer. Furthermore,
Runx1 deﬁciency substantially diminished high-level Runx1 binding at the Cebpe enhancer, but lower-level binding at the Cebpa
enhancer was relatively preserved. Thus, Runx1-deﬁciency permits Cebpa upregulation and the exponential cell growth that
accompanies lineage commitment, but by impairing activation of Cebpe, a key proliferation-terminating maturation gene, extends
this exponential growth. These mechanisms facilitate germline cell or HSC of origin, yet evolution into LIC with lineage-committed
phenotype.
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INTRODUCTION
Known ﬁrst-hits in the multi-hit process of leukemogenesis are
inactivating or dominant-negative mutations in RUNX1.1 These
ﬁrst-hits originate in the germline in familial acute myeloid
leukemia (AML, reviewed in the study by Owen et al.2) and in
hematopoietic stem cells (HSCs) in acquired AML.3–5 Germline or
stem cell origin of the ﬁrst hit is necessary as these cells live long
enough that there is a feasible possibility of secondary genetic
abnormalities (additional hits) that can cooperate for evolution
into AML. However, some of these secondary genetic
abnormalities occur in daughter cells with restricted lineage
potential. This is evident in familial AML, in which neoplastic
evolution does not occur in the germline cells of origin, but is also
true of acquired AML: self-renewing AML cells, also known as
leukemia-initiating cells (LICs) or leukemia stem cells, have a
lineage-committed phenotype by numerous surface markers
(CD34þ 38þ , CLL-1þ , CD71þ , CD90 , c-Kit-),6–16 by strikingly
high expression of lineage-specifying transcription factors such as
CEBPA, PU.1/SPI1 or GATA1,17–19 by inactivation of polycomb
repressor complex 2 components that usually suppress lineage
programs,20 and by the observation that highly recurrent
secondary genetic abnormalities such as FLT3 mutation are not
detected in the HSC compartment.5
Thus, a ﬁrst-hit is present or originates in HSC, but creates
conditions that favor further neoplastic evolution not necessarily
in the HSC compartment itself but in lineage-committed
progenitors. The molecular mechanisms underlying this compart-
ment shift during leukemia evolution have not been a major focus
of investigation and are poorly understood. A better under-
standing of these mechanisms could provide guidance for novel
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treatments that exploit the lineage-committed cellular context of
LIC to thereby spare uncommitted normal HSC.
RESULTS AND DISCUSSION
To investigate a basis for compartment shifts during evolution of
myeloid cancers, lineage-negative HSC from wild-type and Runx1
haploinsufﬁcient mice21 were cultured in granulocyte-colony-
stimulating factor (G-CSF) to force lineage commitment. The
Runx1-haploinsufﬁcient cells demonstrated more rapid and
persistent proliferation than wild-type controls (Figure 1a). This
growth advantage was also apparent in semi-solid media
supplemented with G-CSF: Runx1-haploinsufﬁcient cells produced
a higher number and larger-sized colonies than wild-type control
(Figure 1b). The Runx1-haploinsufﬁcient cells were differentiation-
impaired: after 15 days of culture, Runx1-haploinsufﬁcient cells
included mitotic ﬁgures and immature forms with high nuclear-
cytoplasmic ratios and decreased neutrophilic granulation,
whereas wild-type cells demonstrated mostly mature granulocytes
(Figure 1c). Furthermore, the granulocyte-lineage markers Ly6G
and CD11b were upregulated to a much lesser extent in Runx1-
haploinsufﬁcient cells than in wild-type controls (Figure 1d).
To better understand the molecular mechanisms underlying the
persistent proliferation and impaired differentiation, expression
patterns of key hematopoietic transcription factors that determine
lineage commitment and progressive maturation were examined.
These were Hoxb4 that promotes self-renewal by HSC, Cebpa that
drives granulocyte lineage commitment, and Cebpe that drives
Figure 1. Runx1-haploinsufficient cells are able to lineage commit but have impaired subsequent maturation. Lineage-negative (Lin ) cells were
isolated from bone marrow of Runx1þ / (haploinsufficient) and wild-type (WT) C57BL/6 mice using MACS Lineage Cell Depletion Kit (#130-090-
858, Miltenyi Biotec Inc., Auburn, CA, USA). (a) Cell counts. Cytokine supplementation: 10ng/ml of mSCF and 100ng/ml of thrombopoietin (non-
differentiation promoting conditions) or 10ng/ml of murine stem cell factor, 10ng/ml of mIL-6 and G-CSF 20ng/ml (PeproTech Inc., Rocky Hill, NJ,
USA). Cell numbers were determined by automated cell counter every 3 days during 60 days of culture. Mean±standard deviation. Experiments
performed in triplicate. (b) Colony formation by Runx1þ / and WT Lin cells in semi-solid media. 2 104cells/ml of methylcellulose
(MethoCult GF M3434; Stem Cell Technologies, Vancouver, Canada). Colonies counted and imaged by inverted microscope on day 10
(LeicaDMI6000B inverted microscope, Leica Microsystems, Wetzlar, Germany). Experiments performed in triplicate. ** po0.01, Wilcoxon test.
(c) Runx1þ / and WT cell morphology after 15 days of culture with G-CSF. Cytospins were generated with a Shandon CytoSpinIII (Thermo
Scientific, Pittsburgh, PA, USA; 500 r.p.m., 5min). Air-dryed cells fixed with 100%methanol were Giemsa-stained for visualization using a Leica DMR
light microscope equipped with CCD camera (Leica Microsystems), magnification  630. (d) Ly6G and CD11b granulocyte-lineage marker
expression in Runx1þ / and WT Lin cells on day 0 (D0) and day 7 (D7) of culture with G-CSF. Expression measured by Coulter Epics XL-MCL
flow cytometer and CXP software (Beckman-Coulter, Brea, CA, USA). Antibodies used were anti-mouse Ly6G-FITC (eBiosciences, San Diego, CA,
USA; #551460), anti-mouse CD11b-PE (eBiosciences, #120112), and isotype-matched immunoglobulin control.
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late granulocyte maturation and terminates proliferation.22–27
Repression of Hoxb4 and activation of Cebpa by G-CSF was similar
in wild-type and Runx1-haploinsufﬁcient cells (Figure 2a). Despite
the upregulation of Cebpa, Cebpe activation was signiﬁcantly
decreased in the Runx1-haploinsufﬁcient cells, even after 15 days
of culture with G-CSF (Figure 2a). These observations
were recapitulated at the protein level (Figure 2b). This pattern
of gene expression is also a characteristic of primary AML cells
with mutated RUNX1 and normal cytogenetics: CEBPA was on
average430-fold more expressed than CEBPE and46-fold more
expressed than HOXB4 (Figure 2c). Chromatin-immunoprecipita-
tion analysis showed a basis for differential Cebpa and Cebpe
activation in Runx1-deﬁcient cells: in wild-type cells, Runx1
binding was substantially greater at the Cebpe than at the Cebpa
enhancer28,29 (Figure 2d). Furthermore, Runx1-deﬁciency substan-
tially diminished high level Runx1 binding at the Cebpe enhancer,
Figure 2. Unequal impact of Runx1 deficiency on Runx1 binding at the Cebpa and Cebpe enhancers and on Cebpa and Cebpe activation in
response to G-CSF. (a) Time-course expression of Hoxb4 (key stem cell transcription factor), Cebpa (key lineage-commitment transcription
factor) and Cebpe (key late-differentiation transcription factor) in WT and Runx1þ / lineage-negative (Lin ) cells cultured with G-CSF for 15
days. SYBR Green bound to double-stranded DNA was detected in real-time with the 7500 Fast Real Time PCR System (Applied Biosystems,
Foster City, CA, USA). Relative expression values were calculated by raising 2 to the power of the negative value of delta-delta CT for each
sample. Primer sequences: HoxB4: forward (F): 50-CCAGAATCGGCGCATGA-3, reverse (R): 50-CCCGAGCGGATCTTGGT-30; Cebpa: F: 50-CA
AAGCCAAGAAGTCGGTGGACAA-30; R: 50-TCATTGTCACTGGTCAACTCCAGC-30; Cebpe: F: 50-GCTACAATCCCCTGCAGTACC-30; R: 50-TGCCTTCTT
GCCCTTGTG-30; GAPDH: F: 50-ACCACACTCCATGCCATCAC-30, R:50-TCCACCACCCTGTTGCTGTA-30. Mean±standard deviation. **Po0.01,
Student’s t-test. Experiments performed in triplicate. (b) Cebpa and Cebpe protein expression in WT and Runx1þ / Lin cells cultured
for 15 days with G-CSF. Western blot analyses with the following primary antibodies: anti-Cebpa, anti-Cebpe (Santa Cruz Biotechnology, Dallas,
TX, USA; #SC-61, #SC-25770), anti-b-actin (Sigma-Aldrich, St Louis, MO, USA, A3854); secondary antibodies: anti-Rabbit (GE Healthcare,
Waukesha, WI, USA; NA934) and anti-Mouse (GE Healthcare, NXA931) at 1:5000 and 1:10 000 dilutions, respectively. (c) Gene expression of
CEBPA, CEBPE and HOXB4 in primary AML cells with normal cytogenetics and RUNX1 mutation (TCGA database, n¼ 14). Heatmap by Arraystar
software. (d) Chromatin immunoprecipitation (ChIP) analysis of Runx1þ / and WT cells to evaluate Runx1 binding at the Cepba and Cebpe
enhancers. Enhancers of Cebpa and Cebpe were identified by others using ChIP coupled with deep sequencing.28 ChIP performed using ChIP
Assay Kit (cat#17-295, EMD Millipore, Billerica, MA, USA). 5 106 cells bone marrow (BM) cells from WT and Runx1þ /1 fresh BM cells were
resuspended in 10ml of media and formaldehyde was added to a final concentration of 1% followed by 10min incubation at 37 1C. The media
containing formaldehyde was removed and the cells were washed twice with ice-cold PBS containing protease inhibitor (cat#P8340, Sigma-
Aldrich) and phosphatase inhibitor cocktails (cat#P0044, Sigma-Aldrich). Crosslinked cells were resuspended in SDS lysis buffer (Millipore,
#20–163) and incubated for 10min on ice. These cell pellets were sonicated at 15 s pulses with 45 s hold on ice for a total of 10min of pulsing
at full power (Fisher-Scientific Model #550 Sonic Dismembrator equipped with a microtip probe). Genomic DNA fragments of 200-bp and 1-kb
in size were obtained (confirmed by agarose gel electrophoresis). After centrifugation at 4 1C, the supernatant was pre-cleared with salmon
sperm DNA/Protein A agarose-50% slurry (Millipore, #16–157) for 30min at 4 1C with agitation. A 10% aliquot (vol) of the precleared protein/
DNA mixture was removed and used for subsequent reverse transcription–PCR input quantification. 10 mg of anti-Runx1 ChIP grade antibody
(cat#ab23980, Abcam, Cambridge, MA, USA) was added to the remaining protein/DNA mixture and incubated at 4 1C overnight with rotation.
Salmon sperm DNA/Protein A agarose-50% slurry was added and incubated for 1 h at 4 1C followed by washes with the ChIP assay kit
provided buffers. The immunoprecipitated (IP) complexes were reverse crosslinked at 65 1C for 4 h and DNA was recovered by phenol/
chloroform extraction protocol (Sigma). The IP products were amplified and quantified using real-time PCR. ChIP primer sequences are:21
cepba enhancer left primer, 50- TTCCCGTTTCTGAAATCTGC-30, cebpa enhancer right primer, 50-GGTTGTGGCAAGAAGGTCAC-30 , cebpe enhancer
left primer, 50-GTGTCATGGTCACCCTAGCC-30 and cebpe enhancer right primer, 50-CTGGAGCTAGCAGGGGTTTT-30. Mean±standard deviation
from three independent ChIP experiments. **Po0.001, NS¼not significant, Tukey–Kramer HSD test.
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but lower level binding at the Cebpa enhancer was relatively
preserved (Figure 2d). In other words, RUNX1 is more abundant at,
and presumably more important, for regulating the Cebpe
enhancer than the Cebpa enhancer.
Consistent with the present results, Runx1-haploinsufﬁcient
mice have decreased HSC but increased myeloid progenitors
compared with wild-type controls.21 Similarly, a murine knock-in
model of point-mutated Runx1 demonstrated unaltered HSC
emergence but defects in multiple committed hematopoietic
lineages, and hematopoietic cells containing the leukemia fusion
protein RUNX1-ETO demonstrated delayed granulocytic
differentiation.30,31 Previously, we demonstrated that even
CD34þ 38 subsets of primary AML cells demonstrate this
pattern of very high CEBPA but relatively low HOXB4 and CEBPE
expression compared with normal hematopoietic precursors,
promyelocytes and neutrophils.18,32,33 Ideally, leukemia
treatments would suppress malignant clones but preserve
normal HSC needed to restore blood counts. High expression of
key transcription factors that drive differentiation (for example,
CEBPA, PU.1) could be a difference between LIC and normal HSC
that facilitates this goal, especially since the proliferation-
terminating differentiation genes usually activated by these
transcription factors, although aberrantly suppressed in leukemia
cells (for example, CEBPE), are genetically intact and thus in theory
available for activation. For example, high baseline CEBPA
expression explains rapid restoration of CEBPE expression and
cycle exit by maturation of primary AML cells treated with
corepressor antagonizing drugs (for example, decitabine) or with
FLT3 inhibitors.34 The same treatments preserve self-renewal of
uncommitted normal HSC that do not express high levels of
lineage-specifying transcription factors at baseline.35–37
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